Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany.

Epysqli (eculizumab-aagh) - AffaMed Therap, Samsung, Teva

Ultomiris (ravulizumab-cwvz) - AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/42399762

Daniel Lewkowicz; Danila Seidel; Florian Kron; Isabell Kaufhold; Paul Thomas Brinkkoetter

Jul 4, 2026